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A major obstacle to the development of immunotherapy
for pancreatic ductal adenocarcinoma (PDA) has been
identifying immune relevant antigens that are not
expressed by normal cells. DNA sequencing technologies
that allow for the genome-wide identification of tumor
mutations have shown that human PDAs harbor an aver-
age of 63 mutations (called the “mutome”). Since these
mutations are not present prior to the onset of tumorigen-
esis, each mutation generates a novel and essentially for-
eign antigen (termed “epitope”). Unlike most classical
tumor epitopes, mutome-derived epitopes are uniquely
specific to each patient’s tumor. Furthermore, T cells
recognizing them may avoid immunological tolerance
mechanisms that inhibit or deplete T cells that recognize
classical tumor epitopes that are also expressed by normal
cells. Vaccines designed to activate mutome-specific
T cells have the potential to induce robust and specific
antitumor responses and provide a new approach for
personalized tumor immunotherapy. We are using the
Panc02 murine PDA model to develop and explore the
potential of this approach. Sequence analysis identified
596 point mutations in Panc02 cells, significantly more
than the number found in human PDAs. The NetMHC
prediction server was used to screen for epitopes predicted
to bind H2-Db and H2-Kb. In total, 15 strong candidates
(NetMHC scores <50) and another 85 candidate epitopes
within the limits of prediction (scores <500) were
predicted. We analyzed the in vivo immunogenicity of 81
mutations predicted to generate epitopes with scores
<1000 by immunizing mice with 20mers spanning each
mutation with Poly (I:C) and addavax as adjuvants. IFNg
ELISPOT analysis demonstrated that 14 of the 81 (17.3%)
mutations generated immunogenic CD8+ T cell epitopes,
and 5 of the 14 induced robust IFNg responses (>100
spots per 1x105 T cells). Antitumor efficacy was evaluated
by immunizing mice 3 days following subcutaneous
Panc02 challenge. Only immunization against the 5 robust
peptides was capable of preventing tumor outgrowth, and
was significantly more effective than treatment with GM-
CSF-secreting whole-cell vaccination (GVAX), another
approach currently being investigated in the clinic by our
group. We are currently testing the efficacy of this
approach against larger established tumors and metastatic
liver lesions. We are also working to optimize this
approach by testing additional adjuvants and vaccine
vectors, including recombinant Listeria monocytogenes
that express the mutant gene sequences. Exact epitopes
are being mapped in order to evaluate the utility of MHC-
binding predictions. Ultimately, we intend to translate our
optimized approach into the clinic.
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